Pfizer Settles $345M EpiPen Consumers Suit, But Viatris Marches On
Executive Summary
After four years of litigation, Pfizer has reached a preliminary settlement over allegations that it devised an “illegal scheme” with Viatris’ Mylan establish a monopoly for the EpiPen autoinjector device.
You may also be interested in...
Robert Califf Nominated To Retake FDA Commissioner Role
President Biden’s pick for FDA commissioner should remember many of the hot-button issues that he would face if confirmed to a second stint as the nation's top medtech regulator.
Medtech And US DoJ: EpiPen, Dermagraft Lead 2017 Payouts To Feds
US DoJ collected more than $1bn in penalties from device manufacturers this year, chiefly on false claims and manufacturing violations. Here is a roundup and sortable table of the payouts.
Apotex Moves First On Combigan As US Patent Expiry Looms
Apotex has moved first on Allergan’s Combigan, introducing a US authorized generic as the clock ticks on the originator’s IP. Sandoz is among ANDA sponsors seemingly waiting for patent protection to lapse.